GlassScriptPhysician profile
Sanjay Rajagopalan
NPI 1871582577
$521,330.18
in general payments reported to CMS, 2019-2025
20 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $6,068 · 2021: $110K · 2022: $98K · 2023: $66K · 2024: $124K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $170K · Consulting Fee: $69K · Travel and Lodging: $22K · Food and Beverage: $3,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $170,324.69 |
| Consulting Fee | $68,558.75 |
| Travel and Lodging | $21,781.00 |
| Food and Beverage | $3,365.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $455,286.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $27,870.30 | 2021-2024 | |
| Takeda Pharmaceuticals International, INC. | $19,273.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,502.97 | 2020-2024 | Jardiance |
| Siemens Medical Solutions USA, INC. | $7,198.06 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,334.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $233.12 | 2019-2024 | |
| Boston Scientific Corporation | $164.35 | 2021 | |
| Novo Nordisk As | $124.67 | 2023 | |
| Heartflow, INC. | $112.84 | 2022-2023 | Ffrct |
| Amgen INC. | $47.99 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.22 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $42.40 | 2019-2022 | |
| Amarin Pharma, INC. | $24.94 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.79 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $17.92 | 2020 | |
| Abbott Laboratories | $16.97 | 2021 | |
| Pfizer INC. | $14.85 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Rajagopalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.